Analyzing 4,712 plasma proteins in 9,391 adults over 25 years, researchers identified 144 protein-cancer associations that predicted seven solid cancers long before clinical diagnosis. The study confirmed established markers like PSA (KLK3) for prostate cancer while discovering 33 novel proteins linked to liver cancer and 4 to lung cancer. Remarkably, 90% of identified proteins maintained predictive power even when cancer developed more than five years later, suggesting these represent fundamental biological changes rather than late-stage disease markers. This proteomics approach represents a significant advancement in cancer risk assessment, potentially enabling earlier interventions when treatments are most effective. The findings could revolutionize screening protocols by identifying high-risk individuals decades before symptoms appear, fundamentally shifting cancer care from reactive treatment to proactive prevention. However, this remains a preprint awaiting peer review, and translation to clinical practice requires validation of cost-effectiveness, optimal screening intervals, and psychological impacts of long-term risk prediction. The discovery that blood proteins can signal cancer risk 25 years in advance represents a paradigm shift toward precision prevention, though practical implementation faces substantial logistical and ethical challenges.